JPWO2022255348A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022255348A5 JPWO2022255348A5 JP2023525849A JP2023525849A JPWO2022255348A5 JP WO2022255348 A5 JPWO2022255348 A5 JP WO2022255348A5 JP 2023525849 A JP2023525849 A JP 2023525849A JP 2023525849 A JP2023525849 A JP 2023525849A JP WO2022255348 A5 JPWO2022255348 A5 JP WO2022255348A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- soluble
- acute cerebrovascular
- cerebrovascular disease
- clec2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 69
- 230000001154 acute effect Effects 0.000 claims description 51
- 102100032529 C-type lectin domain family 1 member B Human genes 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 230000001269 cardiogenic effect Effects 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 230000015271 coagulation Effects 0.000 claims description 12
- 238000005345 coagulation Methods 0.000 claims description 12
- 230000020764 fibrinolysis Effects 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 11
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 8
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 8
- 238000012502 risk assessment Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 101000942284 Homo sapiens C-type lectin domain family 1 member B Proteins 0.000 claims 8
- 101710160442 C-type lectin domain family 1 member B Proteins 0.000 description 27
- 210000001772 blood platelet Anatomy 0.000 description 26
- 206010008118 cerebral infarction Diseases 0.000 description 18
- 238000003018 immunoassay Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000003748 differential diagnosis Methods 0.000 description 5
- 239000003154 D dimer Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021091606 | 2021-05-31 | ||
| PCT/JP2022/022076 WO2022255348A1 (ja) | 2021-05-31 | 2022-05-31 | 可溶型ｃｌｅｃ２を用いた急性脳血管障害のリスク評価方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022255348A1 JPWO2022255348A1 (https=) | 2022-12-08 |
| JPWO2022255348A5 true JPWO2022255348A5 (https=) | 2025-03-21 |
Family
ID=84323407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525849A Pending JPWO2022255348A1 (https=) | 2021-05-31 | 2022-05-31 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240264174A1 (https=) |
| EP (2) | EP4636404A3 (https=) |
| JP (1) | JPWO2022255348A1 (https=) |
| KR (1) | KR20240017000A (https=) |
| CN (1) | CN117813505A (https=) |
| WO (1) | WO2022255348A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025075139A1 (ja) * | 2023-10-06 | 2025-04-10 | Ｐｈｃ株式会社 | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6078845U (ja) | 1983-11-04 | 1985-06-01 | ライオン株式会社 | 食用廃油固化処理用具 |
| AU2002359815A1 (en) * | 2001-12-19 | 2003-07-09 | Immunex Corporation | C-type lectin polypeptide, polynucleotide and methods of making and use thereof |
| JP2007070359A (ja) * | 2005-09-06 | 2007-03-22 | Univ Of Yamanashi | 止血疾患治療用の医薬組成物 |
| EP2269597A1 (en) * | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| EP2272874A1 (en) * | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| JP6078845B2 (ja) * | 2012-09-28 | 2017-02-15 | 株式会社Ｌｓｉメディエンス | 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法 |
| US10227407B2 (en) * | 2013-10-10 | 2019-03-12 | Yukinari Kato | Anti-podoplanin antibody |
| JP7172286B2 (ja) | 2018-08-28 | 2022-11-16 | スズキ株式会社 | ニーエアバッグ取付け構造 |
| JP6883348B2 (ja) | 2019-06-26 | 2021-06-09 | 稔 甲斐 | 閉塞防止機能付振動篩用網及び振動篩装置 |
| JP7215389B2 (ja) | 2019-10-08 | 2023-01-31 | 株式会社デンソー | 電子制御装置 |
| EP4113524A4 (en) * | 2020-02-28 | 2024-03-06 | LSI Medience Corporation | METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT |
-
2022
- 2022-05-31 US US18/565,207 patent/US20240264174A1/en active Pending
- 2022-05-31 JP JP2023525849A patent/JPWO2022255348A1/ja active Pending
- 2022-05-31 KR KR1020237044827A patent/KR20240017000A/ko active Pending
- 2022-05-31 WO PCT/JP2022/022076 patent/WO2022255348A1/ja not_active Ceased
- 2022-05-31 EP EP25193124.2A patent/EP4636404A3/en active Pending
- 2022-05-31 EP EP22816094.1A patent/EP4350349A4/en active Pending
- 2022-05-31 CN CN202280038994.9A patent/CN117813505A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7546037B2 (ja) | 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法 | |
| WO2009059404A1 (en) | Angiopoietin-1 and -2 biomarkers for infectious diseases that compromise endothelial integrity | |
| KR20180118822A (ko) | 패혈증 예후의 예측 방법 | |
| JP6108409B2 (ja) | 播種性血管内凝固症候群または感染性播種性血管内凝固症候群を検出する方法 | |
| JP2006510895A (ja) | Ｃｖｄ分析 | |
| JP2009539080A (ja) | 急性冠状動脈症候群のリスクを有する個体の識別のためのｍｒｐ８／１４レベルの使用 | |
| CN105021827A (zh) | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 | |
| JPWO2022255348A5 (https=) | ||
| JPWO2005080982A1 (ja) | Ａ型及びｂ型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット | |
| JP7348604B2 (ja) | パーキンソン病の診断を補助する方法、バイオマーカー、試薬キット及び装置 | |
| JPWO2022255349A5 (https=) | ||
| JP2000193662A (ja) | 尿中シスタチンｃ測定試薬及び診断方法並びにキット | |
| US10663472B2 (en) | Method for evaluating the risk of mortality in patients who exhibit a systemic inflammatory response syndrome (SIRS) or sepsis | |
| EP4350350A1 (en) | Method for assessing risk of hemorrhagic stroke using soluble clec2 | |
| WO2022255348A1 (ja) | 可溶型ｃｌｅｃ２を用いた急性脳血管障害のリスク評価方法 | |
| JP4580869B2 (ja) | 急性大動脈解離の判定方法及び判定用試薬 | |
| CN204330776U (zh) | 一种心肌梗塞快速检测胶体金试剂盒 | |
| CN114660285A (zh) | 一种子痫前期测定试剂盒、制备方法及应用 | |
| JP2024027767A (ja) | 可溶型ｃｌｅｃ２を用いた血小板減少性疾患の診断法 | |
| CN204330770U (zh) | 一种心肌梗塞检测胶体金试剂盒 | |
| Elged et al. | Soluble fibrin monomer complex assay enhances early and accurate diagnosis of acute myocardial infarction | |
| JP7695113B2 (ja) | 可溶型ｃｌｅｃ２を用いたウイルス性肺炎のリスク評価法 | |
| RU2789822C1 (ru) | Способ оптимизации лабораторной диагностики тромбинемии у пациентов с инфекцией COVID-19 | |
| Ashour et al. | Serum and ascitic fluid high sensitive C reactive protein as prognostic marker in patients with spontaneous bacterial peritonitis | |
| WO2025075139A1 (ja) | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 |